Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials

Background: Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) as the commonly used renin-angiotensin aldosterone system inhibitor are widely used in patients with IgA nephropathy (IgAN), but the effect is controversy. In this study, we used a meta-analysis to eva...

Full description

Bibliographic Details
Main Authors:	Yu ZHAO, Heng FAN, Bei-Yan BAO
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2019-09-01
Series:	Iranian Journal of Public Health
Subjects:	Angiotensin converting enzyme inhibitor Angiotensin receptor blocker IgA nephropathy Meta-analysis
Online Access:	https://ijph.tums.ac.ir/index.php/ijph/article/view/18244

Similar Items

Possible beneficial association between renin-angiotensin-aldosterone-system blockade usage and graft prognosis in allograft IgA nephropathy: a retrospective cohort study
by: Sehoon Park, et al.
Published: (2019-09-01)

Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis
by: Pingping Yang, et al.
Published: (2018-12-01)

Comparing the Efficacy of Angiotensin Converting Enzyme Inhibitors with Calcium Channel Blockers on the Treatment of Diabetic Nephropathy: A Meta-Analysis
by: Zhaowei ZHANG, et al.
Published: (2019-02-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Severity of arterial and/or arteriolar sclerosis in IgA nephropathy and the effects of renin–angiotensin system inhibitors on its prognosis
by: Naoko Sugiura, et al.
Published: (2021-11-01)

Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study
by: Melissa Y. Y. Moey, et al.
Published: (2019-07-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study
by: Soumita Bagchi, et al.
Published: (2021-06-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades
by: Byeong Yun Yang, et al.
Published: (2012-09-01)

A high sodium intake reduces antiproteinuric response to renin–angiotensin–aldosterone system blockade in kidney transplant recipients
by: Elena Monfá, et al.
Published: (2016-09-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis
by: Qiong Ling, et al.
Published: (2018-02-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
by: Andrea Laurentius, et al.
Published: (2021-02-01)

The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease
by: Stine Andersen, et al.
Published: (2016-06-01)

Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19
by: Angela Madalina Lazar
Published: (2021-07-01)

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria
by: Feng-Yi Hsu, et al.
Published: (2017-06-01)

IgA Vasculitis and IgA Nephropathy: Same Disease?
by: Evangeline Pillebout
Published: (2021-05-01)

IgA nephropathy associated with axial spondyloarthritis responding to treatment by etanercept: A case report
by: O. Saidane, et al.
Published: (2020-10-01)

Renin-angiotensin system blockers and COVID-19
by: Emmanuelle Vidal-Petiot, et al.
Published: (2021-06-01)

Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis
by: M. E. Ougaard, et al.
Published: (2018-10-01)

Add-On Effect of Angiotensin Receptor Blockade (Candesartan) on Clinical Remission in Active IgA Nephropathy Patients Treated with Steroid Pulse Therapy and Tonsillectomy: a Randomized, Parallel-Group Comparison Trial
by: Kentaro Kohagura, et al.
Published: (2018-05-01)

History of IgA Nephropathy Mouse Models
by: Batoul Wehbi, et al.
Published: (2021-07-01)

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
by: Chee Kay Cheung, et al.
Published: (2021-06-01)

Clinical Relevance of Serum Galactose Deficient IgA1 in Patients with IgA Nephropathy
by: Jin Sug Kim, et al.
Published: (2020-11-01)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
by: Monika Cahova, et al.
Published: (2021-03-01)

Predictors of prognosis in IgA nephropathy
by: Yasuhiko Tomino
Published: (2012-10-01)

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy
by: Pei Chen, et al.
Published: (2018-10-01)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study
by: Jenny I. Shen, et al.
Published: (2017-06-01)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications
by: Neiberg de Alcantara Lima, et al.
Published: (2020-06-01)

Treatment of hypertension during the COVID-19 pandemic: questions about the blockade of the renin-angiotensin-aldosterone system
by: S. G. Kanorskiy
Published: (2021-04-01)

Renin-angiotensin and kallikrein-kinin systems in diabetic renal damage
by: Igić Rajko
Published: (2019-01-01)

Transforming growth factor-β in diabetic nephropathy
by: Karima Y. Ahmed, et al.
Published: (2013-01-01)

Assessment of Anti-Hypertensive Drug Adherence by Serial Aldosterone-To-Renin Ratio Measurement
by: Fabrizio Buffolo, et al.
Published: (2021-05-01)

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease
by: Mona A. Abdelrahman, et al.
Published: (2016-09-01)

Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic
by: Simon B. Gressens, et al.
Published: (2021-02-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Cannot write session to /tmp/vufind_sessions/sess_se2744114m1vc3fdcb7cci4vrq